Foresite Capital Management V, LLC Diversified Active

Name: Foresite Capital Management V, LLC Q1 2022 13F Filing | 13F Explorer
Creator: Foresite Capital Management V, LLC
Published: 2022-05-13

Location: West Hollywood, CA

CIK: 0001792206 · Show all filings

Period: Q1 2022 (← Previous) (Next →)

Filing Date: May 13, 2022

Total Value: $245M (100.0% shares, 0.0% debt)

Holdings (17)

— Pardes Biosciences Inc 27.7%

Value $67.87M Shares 9,400,515 Est. Cost $16.37 Unrealized —

— Theseus Pharmaceuticals, Inc. 15.1%

Value $37.04M Shares 3,212,732 Est. Cost $12.68 Unrealized —

— Somalogic, Inc. 12.2%

Value $29.89M Shares 3,726,472 Est. Cost $12.39 Unrealized —

ACRS Aclaris Therapeutics, Inc. 8.9%

Value $21.69M Shares 1,258,243 Est. Cost $19.56 Unrealized -30.2%

HIMS Hims & Hers Health, Inc. 5.9%

Value $14.43M Shares 2,706,922 Est. Cost $10.11 Unrealized -51.1%

— Adicet Bio, Inc. 5.5%

Value $13.58M Shares 680,000 Est. Cost $17.49 Unrealized —

QSI Quantum-Si Incorporated 4.5%

Value $10.96M Shares 2,342,061 Est. Cost $10.48 Unrealized -53.5%

CGEM Cullinan Oncology, Inc. 4.2%

Value $10.39M Shares 992,507 Est. Cost $40.60 Unrealized -66.7%

— Kinnate Biopharma Inc. 4.0%

Value $9.853M Shares 875,001 Est. Cost $39.78 Unrealized —

IVVD Adagio Therapeutics, Inc. 2.7%

Value $6.529M Shares 1,431,826 Est. Cost $34.15 Unrealized -82.1%

CMPX Compass Therapeutics, Inc. 2.5%

Value $6.028M Shares 4,400,000 Est. Cost $3.29 Unrealized -37.2%

— Research Alliance Corp. II 2.0%

Value $4.88M Shares 500,000 Est. Cost $10.25 Unrealized —

— Gemini Therapeutics, Inc. 1.4%

Value $3.385M Shares 2,435,125 Est. Cost $13.55 Unrealized —

HLTHQ Cue Health Inc. 1.3%

Value $3.164M Shares 490,546 Est. Cost $11.81 Unrealized —

ENTA Enanta Pharmaceuticals, Inc. 1.2%

Value $3.007M Shares 42,250 Est. Cost $65.07 Unrealized 0.0%

— 23andMe Holding Co. 0.6%

Value $1.558M Shares 406,913 Est. Cost $11.69 Unrealized —

PHVS Pharvaris N.V. 0.3%

Value $619K Shares 34,142 Est. Cost $31.46 Unrealized -44.1%

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Pardes Biosciences Inc	9,400,515	$67.87M	27.7%	$16.37	—	COM	69945Q105
—	Theseus Pharmaceuticals, Inc.	3,212,732	$37.04M	15.1%	$12.68	—	COM	88369M101
—	Somalogic, Inc.	3,726,472	$29.89M	12.2%	$12.39	—	COM CL A	83444K105
ACRS	Aclaris Therapeutics, Inc.	1,258,243	$21.69M	8.9%	$19.56	-30.2%	COM	00461U105
HIMS	Hims & Hers Health, Inc.	2,706,922	$14.43M	5.9%	$10.11	-51.1%	COM CL A	433000106
—	Adicet Bio, Inc.	680,000	$13.58M	5.5%	$17.49	—	COM	007002108
QSI	Quantum-Si Incorporated	2,342,061	$10.96M	4.5%	$10.48	-53.5%	COM CL A	74765K105
CGEM	Cullinan Oncology, Inc.	992,507	$10.39M	4.2%	$40.60	-66.7%	COM	230031106
—	Kinnate Biopharma Inc.	875,001	$9.853M	4.0%	$39.78	—	COM	49705R105
IVVD	Adagio Therapeutics, Inc.	1,431,826	$6.529M	2.7%	$34.15	-82.1%	COM	00534A102
CMPX	Compass Therapeutics, Inc.	4,400,000	$6.028M	2.5%	$3.29	-37.2%	COM	20454B104
—	Research Alliance Corp. II	500,000	$4.88M	2.0%	$10.25	—	COM CL A	760873109
—	Gemini Therapeutics, Inc.	2,435,125	$3.385M	1.4%	$13.55	—	COM	36870G105
HLTHQ	Cue Health Inc.	490,546	$3.164M	1.3%	$11.81	—	COM	229790100
ENTA	Enanta Pharmaceuticals, Inc.	42,250	$3.007M	1.2%	$65.07	0.0%	COM	29251M106
—	23andMe Holding Co.	406,913	$1.558M	0.6%	$11.69	—	COM CL A	90138Q108
PHVS	Pharvaris N.V.	34,142	$619K	0.3%	$31.46	-44.1%	COM	N69605108